

Amendments to the Claims:


This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

1-3. (Cancelled)

4. (Currently amended): An EPO receptor complex ~~A combination in other than a human comprising~~ having a polypeptide comprising a [[the]] modulating domain sequence of ~~the~~ an erythropoietin receptor and a non-peptide organic molecule of from 12 to 36 atoms other than hydrogen, from 9 to 20 carbon atoms, and from 4 to 12 of the heteroatoms chalcogen, nitrogen, halogen, and metal ion of Groups I and II of the periodic chart, and of the formula:

(1)



wherein:

X is of from 1 to 3 atoms other than hydrogen and is oxygen, sulfur bonded to 0 to 2 oxygen atoms, amino and alkyl substituted amino;

n is 0 or 1;

R₁ is a lower alkyl group of 1 to 3 carbon atoms or an organic group having a six annular membered aromatic group having from 0 to 3 substituents, where the substituents are halo, lower alkyl of from 1 to 3 carbon atoms, nitro, trihalomethyl, and is either directly bonded to X or bonded through a linking group of from 1 to 4 carbon, nitrogen, or chalcogen atoms in the chain, ~~being particularly carbon and nitrogen, and~~ there being from 0 to 2 heteroatoms in the chain, where heteroatoms are bonded solely to carbon and hydrogen, or alpha-acetamidinyl having from 0 to 1 N-OH;

R₂ is hydrogen, amino of 0 to 3 carbon atoms, oxy of from 0 to 3 carbon atoms, or a heterofunctionality having nitrogen or chalcogen bonded to annular carbon [[to]] which is substituted with an organic group of from 1 to 10 carbon atoms and from 0 to 3 heteroatoms;

R₃ is hydrogen or an organic group of from 1 to 10 carbon atoms and from 0 to 4 chalcogen and nitrogen heteroatoms; and

R₄ is hydrogen, alkyl or substituted alkyl of from 1 to 6 carbon atoms, where the substituents are oxy, amino and halo;

with the proviso that R₃ and R₄ can be taken together to form a ring with the annular atoms to which they are attached of from 4 to 10 annular atoms and forming from 1 to 2 rings, where the annular atoms are unsubstituted or substituted with halo, alkyl of from 1 to 3 carbon atoms, oxy of from 0 to 3 carbon atoms, thio of from 0 to 3 carbon atoms [[and]] or amino of from 0 to 4 carbon atoms.

5. (Currently amended): A complex combination according to Claim 4, wherein R₃ is hydrogen or an organic group of from 1 to 8 carbon atoms and 0 to 4 chalcogen, nitrogen [[and]] or halo heteroatoms.

6. (Currently amended): A complex combination according to Claim 5, wherein R₃ is cyclopropylmethylamino.


7. (Currently amended): A complex combination according to Claim 5, wherein R₃ is H.

8. (Currently amended): A complex combination according to Claim 4, wherein R₁ is a six annular membered aromatic group having from 0 to 3 substituents, where the substituents are halo, lower alkyl of from 1 to 3 carbon atoms, nitro, or trihalomethyl, and is either directly bonded to X or bonded through a linking group of from 1 to 4 carbon, nitrogen, or chalcogen atoms in the chain.

9. (Currently amended): A complex combination according to Claim 4, wherein R₄ is methyl.

10. (Currently amended): A complex combination according to Claim 4, wherein R₄ is H.

11. (Currently amended): An EPO receptor complex having ~~A combination in other than a human~~ comprising a polypeptide comprising [[the]] a modulating sequence of [[the]] an erythropoietin receptor and a non-peptide organic molecule of from 12 to 36 atoms other than hydrogen, from 9 to 20 carbon atoms, and from 4 to 12 of the heteroatoms chalcogen, nitrogen, halogen, and metal ion of Groups I and II of the periodic chart, and of the formula:



(3)

wherein:

Y is O, S(O)_m, wherein m is 0, 1 or 2, amino or CH₂;

R₆ is H or alkyl of from 1 – 3 carbon atoms;

R₇ is hydrogen, or a group of from 0 to 3 atoms other than hydrogen, and is oxy, thio, amino, nitro, cyano, and alkyl;


V is a phenyl group;

U is oxy, thio, amino, nitro, cyano, halo, and alkyl and from 0 to 3 atoms other than hydrogen; and u is 0 to 3.

12. (Currently amended): A complex combination according to Claim 11, wherein Y is SO₂, V is phenyl, R₇ is Cl and u is 0.

13. (Currently amended): An EPO receptor complex having ~~A combination in other than a human comprising~~ a polypeptide comprising a [[the]] modulating domain sequence of an ~~[[the]]~~ erythropoietin receptor and a non-peptide organic molecule of from 12 to 36 atoms other than hydrogen, from 9 to 20 carbon atoms, and from 4 to 12 of the heteroatoms chalcogen, nitrogen, halogen, and metal ion of Groups I and II of the periodic chart, and of the formula:

(1)



wherein:

X is of from 1 to 3 atoms other than hydrogen and is oxygen, sulfur bonded to 0 to 2 oxygen atoms, amino and alkyl substituted amino;

n is 0 or 1;

R₁ is alkyl of from 1 to 3 carbon atoms, substituted phenyl having from 0 to 3 substituents that are CH₃, Cl, NO₂, and CF₃ and bonded directly to an annular carbon atom, or through a linking group of from 1 to 3 carbon and nitrogen atoms in the chain or N-hydroxyamidinyl;

R₂ is CH₃, NH₂, OH, or [[and]] aroylamido of from 7 to 8 carbon atoms having from 0 to 2 substituents that are CH₃, Cl, NO₂, and CF₃;

R₃ is cycloalkylalkyl of from 4 to 8 carbon atoms, having from 3 to 4 annular atoms, H or carboxy;

R₄ is H, lower alkyl of from 1 to 3 carbon atoms or alkoxymethyl of from 2 to 4 carbon atoms;


with the proviso that R₃ and R₄ may be taken together to define 1,2-dimethylene-alpha-halo, or alpha-CH₃-halobenzene, where halo is F or Cl.

14-25. (Cancelled)

26. (Currently amended): A pharmaceutical composition comprising:

in a pharmacologically effective amount for modulating EPO-R activity, a non-peptide organic molecule of from 12 to 36 atoms other than hydrogen, from 9 to 20 carbon atoms, [[and]] from 4 to 12 of the heteroatoms chalcogen, nitrogen, halogen, and a metal ion of Groups I and II of the periodic chart, and of the formula:

(1)



wherein:

X is of from 1 to 3 atoms other than hydrogen and is oxygen, sulfur bonded to 0 to 2 oxygen atoms, amino [[and]] or alkyl substituted amino;
n is 0 or 1;

R₁ is alkyl of from 1 to 3 carbon atoms, substituted phenyl having from 0 to 3 substituents that are CH₃, Cl, NO₂, [[and]] or CF₃, and R₁ is bonded directly to an annular carbon atom or through a linking group of from 1 to 3 carbon and nitrogen atoms in the chain or N-hydroxyamidinyl;

R₂ is CH₃, NH₂, OH, and aroylamido of from 7 to 8 carbon atoms having from 0 to 2 substituents that are CH₃, Cl, NO₂, [[and]] or CF₃;

R₃ is cycloalkylalkyl of from 4 to 8 carbon atoms, having from 3 to 4 annular atoms, H or carboxy;

R₄ is H, lower alkyl of from 1 to 3 carbon atoms or alkoxymethyl of from 2 to 4 carbon atoms;


with the proviso that R₃ and R₄ may be taken together to define 1,2-dimethylene-alpha-halo, or alpha-CH₃-halobenzene, where halo is F or Cl

and a pharmaceutically acceptable vehicle.

27. (Previously presented): A pharmaceutical composition comprising:

in a pharmacologically effective amount for modulating EPO-R activity, a non-peptide organic molecule of from 12 to 36 atoms other than hydrogen, from 9 to 20 carbon atoms, and from 4 to 12 of the heteroatoms chalcogen, nitrogen, halogen, and metal ion of Groups I and II of the periodic chart, and of the formula:

(3)



wherein:

Y is O, S(O)_m, wherein m is 0, 1 or 2, amino or CH₂;

R₆ is H or alkyl of from 1 – 3 carbon atoms;

R₇ is hydrogen, or a group of from 0 to 3 atoms other than hydrogen, and is oxy, thio amino, nitro, cyano, and alkyl;

V is a phenyl group;

U is oxy, thio amino, nitro, cyano, halo, and alkyl and from 0 to 3 atoms other than hydrogen; and u is 0 to 3, and a pharmaceutically acceptable vehicle.


28. (Withdrawn): A method of determining the binding affinity of a test compound to the modulating domain of EPO-R, said method comprising:

adding said test compound to a combination according to Claim 1 and determining the amount of complex of said combination in the presence of said test compound as compared to the absence of said test compound.

29. (Currently amended): A method of inducing a physiological response of EPO-R in a host, said method comprising:

administering to said host a physiologically effective amount of a non-peptide organic molecule of from 12 to 36 atoms other than hydrogen, from 9 to 20 carbon atoms, and from 4 to 12 of the heteroatoms chalcogen, nitrogen, halogen, and metal ion of Groups I and II of the periodic chart, and of the formula:

(1)



wherein:

X is of from 1 to 3 atoms other than hydrogen and is oxygen, sulfur bonded to 0 to 2 oxygen atoms, amino and alkyl substituted amino;
n is 0 or 1;

R₁ is alkyl of from 1 to 3 carbon atoms, substituted phenyl having from 0 to 3 substituents that are CH₃, Cl, NO₂, and CF₃ and bonded directly to an annular carbon atom or through a linking group of from 1 to 3 carbon and nitrogen atoms in the chain, N-hydroxyamidinyl;


R₂ is CH₃, NH₂, OH, and aroylamido of from 7 to 8 carbon atoms having from 0 to 2 substituents that are CH₃, Cl, NO₂, and CF₃;

R₃ is cycloalkylalkyl of from 4 to 8 carbon atoms, having from 3 to 4 annular atoms, H or carboxy;

R₄ is H, lower alkyl of from 1 to 3 carbon atoms or alkoxymethyl of from 2 to 4 carbon atoms;

with the proviso that R₃ and R₄ may be taken together to define 1,2-dimethylene-alpha-halo, alpha-CH₃-halobenzene, where halo is F or Cl; or

(2)



wherein:

~~X is of from 1 to 3 atoms other than hydrogen and is oxygen, sulfur bonded to 0 to 2 oxygen atoms, amino and alkyl substituted amino;~~
~~n is 0 or 1;~~

Y is O, S(O)_m, wherein m is 0, 1 or 2, amino or CH₂;

R₆ is H or alkyl of from 1 – 3 carbon atoms;

R₇ is hydrogen, or a group of from 0 to 3 atoms other than hydrogen, and is oxy, thio amino, nitro, cyano, and alkyl;

V is a phenyl group;

U is oxy, thio amino, nitro, cyano, halo, and alkyl and from 0 to 3 atoms other than hydrogen; and u is 0 to 3.


30. (Withdrawn): A method according to Claim 29, wherein said non-peptide organic molecule is of formula 1.

31. (Withdrawn): A method according to Claim 30, wherein X is amino, R₂ is o-methyl, p-chlorophenyl-1, R₂ is H, R₃ is cyclopropylmethylamino and R₄ is methyl.

32. (Currently amended): A method of modulating the response to a stimulus of hematopoietic or neuronal cells influenced by the binding of EPO to EPO-R, said method comprising:

contacting said cells with an effective amount to modulate said response of a non-peptide organic molecule of from 12 to 36 atoms other than hydrogen, from 9 to 20 carbon atoms, and from 4 to 12 of the heteroatoms chalcogen, nitrogen, halogen, and metal ion of Groups I and II of the periodic chart, and of the formula:

(1)



wherein:

R₁ is alkyl of from 1 to 3 carbon atoms, substituted phenyl having from 0 to 3 substituents that are CH₃, Cl, NO₂, and CF₃ and bonded directly to an annular carbon atom or through a linking group of from 1 to 3 carbon and nitrogen atoms in the chain, N-hydroxyamidinyl;


R₂ is CH₃, NH₂, OH, and aroylamido of from 7 to 8 carbon atoms having from 0 to 2 substituents that are CH₃, Cl, NO₂, and CF₃;

R₃ is cycloalkylalkyl of from 4 to 8 carbon atoms, having from 3 to 4 annular atoms, H or carboxy;

R₄ is H, lower alkyl of from 1 to 3 carbon atoms or alkoxymethyl of from 2 to 4 carbon atoms;

with the proviso that R₃ and R₄ may be taken together to define 1,2-dimethylene-alpha-halo, alpha-CH₃-halobenzene, where halo is F or Cl; or

(3)



wherein:

Y is O, S(O)_m, wherein m is 0, 1 or 2, amino or CH₂;

R₆ is H or alkyl of from 1 – 3 carbon atoms;


R₇ is hydrogen, or a group having ~~of from~~ 0 to 3 atoms other than hydrogen, and is oxy, thio amino, nitro, cyano, or ~~[[and]]~~ alkyl;

V is a phenyl group; and

U is oxy, thio amino, nitro, cyano, halo, and alkyl and from 0 to 3 atoms other than hydrogen; and u is 0 to 3.

33-35. (Cancelled)

36. (Currently amended): A pharmaceutical composition comprising:
in a pharmacologically effective amount for modulating EPO-R activity, a non-peptide diazoloheptahydroquinoline organic molecule of from 12 to 36 atoms other than hydrogen, from 9 to 20 carbon atoms, and from 4 to 12 of the heteroatoms chalcogen, nitrogen, halogen, and metal ion of Groups I and II of the periodic chart, and of the formula:



wherein:

Y is oxygen, sulfur, NH, [[()]alkyl of from 1 to 3 carbon atoms, H[()]] or H₂


R₇ is hydrogen or an organic group of from 1 to 12 carbon atoms and 0 to 4 heteroatoms;

R₈ is hydrogen, an aliphatic group of from 1 to 6 carbon atoms or a heterocycle of from 5 to 6 annular members and from 1 to 2 heteroannular members that are oxygen, nitrogen or sulfur;
and

R₉, R₁₀, R₁₃, R₁₄, R₁₅ and R₁₆ are the same or different and are hydrogen or an organic radical of from 1 to 12 carbon atoms or a heterosubstituent of from 1 to 3 heteroatoms;


R₁₁ and R₁₂ are the same or different and are hydrogen or an organic group of from 1 to 12 carbon atoms, and a pharmaceutically acceptable vehicle.

37. (Previously presented): A pharmaceutical composition according to claim 36, wherein said diazoloheptahydroquinoline is of the formula:



38. (New): An EPO receptor complex comprising a polypeptide having a modulating sequence of an erythropoietin receptor and a non-peptide organic molecule of from 12 to 36 atoms other than hydrogen, from 9 to 20 carbon atoms, and from 4 to 12 of the heteroatoms chalcogen, nitrogen, halogen, and metal ion of Groups I and II of the periodic chart, and of the formula:

(1)



wherein:

X is of from 1 to 7 atoms other than hydrogen and is oxygen, sulfur bonded to 0 to 2 oxygen atoms, amino and alkyl substituted amino;

n is 0 or 1;

R₁ is hydrogen or an organic group of from 1 to 12 carbon atoms and from 0 to 6 heteroatoms, which are chalcogen, nitrogen, or halogen, consisting of an aliphatic group of from 1 to 6 carbon atoms having from 0 to 2 sites of unsaturation, non-oxo-carbonyl and the nitrogen and sulfur derivatives thereof, alicyclic having from 0 to 2 sites of unsaturation, aryl, heterocyclic and combinations thereof, where the cyclic structures may have from 1 to 2 rings;


R₂ is hydrogen, a heterofunctionality having nitrogen and/or chalcogen bonded to annular carbon, a heterofunctionality having nitrogen and/or chalcogen bonded to annular carbon to which is substituted with an organic group of from 1 to 10 carbon atoms, aryl, alkaryl, aralkyl and aralkenyl of from 5 to 10 carbon atoms, aroyl of from 6 to 10 carbon atoms, or an organic group bonded through a carbon atom of from 1 to 12 carbon atoms having from 1 to 4 heteroatoms, which are chalcogen, nitrogen or halogen;

R₃ is hydrogen or an organic group of from 1 to 10 carbon atoms and from 0 to 4 chalcogen and nitrogen heteroatoms;

R₄ is hydrogen or alkyl and substituted alkyl of from 1 to 6 carbon atoms, where the substituents are oxy, amino and halo;

with the proviso that R₃ and R₄ can be taken together to form a ring with the annular atoms to which they are attached of from 4 to 10 annular atoms and forming from 1 to 2 rings, where the annular atoms are unsubstituted or substituted with halo, alkyl of from 1 to 3 carbon atoms, oxy of from 0 to 3 carbon atoms, thio of from 0 to 3 carbon atoms and amino of from 0 to 4 carbon atoms;

(2)




wherein:

p is 0, 1 or 2; and

R_5 has from 1 to 3 atoms other than hydrogen and is oxy, thio, amino, nitro, cyano, and alkyl;

(3)



wherein:

Y is amino, CH_2 , O, or $S(O)_m$, wherein m is 0, 1 or 2;

R_6 is H or alkyl of from 1 – 3 carbon atoms;


R_7 is hydrogen, or a group having 0 to 3 atoms other than hydrogen, and is oxy, thio amino, nitro, cyano, or alkyl;

V is an aryl group having 6 annular members comprising 0 to 2 nitrogen atoms, the remainder being carbon atoms;

U is a substituent of from 0 to 5 atoms other than hydrogen, and is oxy, thio amino, nitro, cyano, halo, or alkyl; and

u is 0 to 3; or

(4) diazolohehexahydroquinoline of the structure given below:



wherein:

Z is oxygen, sulfur, NH, alkyl of from 1 to 3 carbon atoms, H or H₂;

R₇ is hydrogen or an organic group of from 1 to 12 carbon atoms and 0 to 4 heteroatoms;

R₈ is hydrogen, an aliphatic group of from 1 to 6 carbon atoms or a heterocycle of from 5 to 6 annular members and from 1 to 2 heteroannular members that are oxygen, nitrogen or sulfur; and

R₉, R₁₀, R₁₃, R₁₄, R₁₅ and R₁₆ are the same or different and are hydrogen or an organic radical of from 1 to 12 carbon atoms or a heterosubstituent of from 1 to 3 heteroatoms;

R₁₁ and R₁₂ are the same or different and are hydrogen or an organic group of from 1 to 12 carbon atoms.

39. (New): A complex according to Claim 38, wherein said polypeptide and said non-peptide organic molecule are complexed at the modulating domain of EPO-R.

40. (New): A complex according to Claim 39, wherein said polypeptide is EPO-R bound to a cellular membrane.

41. (New): An EPO receptor complex having a modulating sequence of an erythropoietin receptor and a non-peptide organic molecule of from 12 to 36 atoms other than hydrogen, from 9 to 20 carbon atoms, and from 4 to 12 of the heteroatoms chalcogen, nitrogen, halogen, and metal ion of Groups I and II of the periodic chart, and of the formula of

diazolohexahydroquinoline of formula (4) of Claim 38,

wherein:

Z is oxygen, sulfur, NH, alkyl of from 1 to 3 carbon atoms, H or H₂;

R₇ is hydrogen or an organic group of from 1 to 12 carbon atoms and 0 to 4 heteroatoms;


R₈ is hydrogen, an aliphatic group of from 1 to 6 carbon atoms or a heterocycle of from 5 to 6 annular members and from 1 to 2 heteroannular members that are oxygen, nitrogen or sulfur; and

R₉, R₁₀, R₁₃, R₁₄, R₁₅ and R₁₆ are the same or different and are hydrogen or an organic radical of from 1 to 12 carbon atoms or a heterosubstituent of from 1 to 3 heteroatoms;


R₁₁ and R₁₂ are the same or different and are hydrogen or an organic group of from 1 to 12 carbon atoms.

42. (New): A complex according to claim 38, wherein said

diazolohexahydroquinoline is of the formula:



43. (New): A method for modulating the activity of EPO-R, present as a cell membrane component, comprising: forming an EPO-R:diazoloheptahydroquinoline complex by contacting said EPO-R with an effective amount of a diazoloheptahydroquinoline of the formula:



wherein:

Z is oxygen, sulfur, NH, alkyl of from 1 to 3 carbon atoms, or H₂;

R₇ is hydrogen or an organic group of from 1 to 12 carbon atoms and 0 to 4 heteroatoms;


R₈ is hydrogen, an aliphatic group of from 1 to 6 carbon atoms or a heterocycle of from 5 to 6 annular members and from 1 to 2 heteroannular members that are oxygen, nitrogen or sulfur;
and

R₉, R₁₀, R₁₃, R₁₄, R₁₅ and R₁₆ are the same or different and are hydrogen or an organic radical of from 1 to 12 carbon atoms or a heterosubstituent of from 1 to 3 heteroatoms;

R₁₁ and R₁₂ are the same or different and are hydrogen or an organic group of from 1 to 12 carbon atoms,


wherein said diazoloheptahydroquinoline binds to said EPO-R in said cell membrane.

44. (New): A method for modulating the activity of EPO-R according to claim 43 wherein said diazoloheptahydroquinoline is of the formula:



45. (New): A method for modulating the activity of EPO-R, present as a cell membrane component comprising: forming an EPO-R:non-peptide organic molecule complex by contacting said EPO-R with an effective amount of said non-peptide organic molecule of from 12 to 36 atoms other than hydrogen, from 9 to 20 carbon atoms, and from 4 to 12 of the heteroatoms chalcogen, nitrogen, halogen, and metal ion of Groups I and II of the periodic chart, and of the formula:

(1)



wherein:

X is of from 1 to 7 atoms other than hydrogen and is oxygen, sulfur bonded to 0 to 2 oxygen atoms, amino and alkyl substituted amino;

n is 0 or 1;

R₁ is hydrogen or an organic group of from 1 to 12 carbon atoms and from 0 to 6 heteroatoms, which heteroatoms are chalcogen, nitrogen, or halogen, said organic group further consisting of an aliphatic group of from 1 to 6 carbon atoms having from 0 to 2 sites of unsaturation, non-oxo-carbonyl and the nitrogen and sulfur derivatives thereof, or alicyclic having from 0 to 2 sites of unsaturation, aryl, heterocyclic and combinations thereof, where the cyclic structures may have from 1 to 2 rings;

R₂ is hydrogen, a heterofunctionality having nitrogen and/or chalcogen bonded to annular carbon, a heterofunctionality having nitrogen and/or chalcogen bonded to annular carbon to which is substituted with an organic group of from 1 to 10 carbon atoms, aryl, alkaryl, aralkyl and aralkenyl of from 5 to 10 carbon atoms, aroyl of from 6 to 10 carbon atoms, or an organic group bonded through a carbon atom of from 1 to 12 carbon atoms having from 1 to 4, heteroatoms as recited for R₁;


R₃ is hydrogen or an organic group of from 1 to 10 carbon atoms and from 0 to 4 chalcogen or nitrogen heteroatoms;

R₄ is hydrogen or alkyl and substituted alkyl of from 1 to 6 carbon atoms, where the substituents are oxy, amino or halo;

with the proviso that R₃ and R₄ can be taken together to form a ring with the annular atoms to which they are attached of from 4 to 10 annular atoms and forming from 1 to 2 rings, where the annular atoms are unsubstituted or substituted with halo, alkyl of from 1 to 3 carbon

atoms, oxy of from 0 to 3 carbon atoms, thio of from 0 to 3 carbon atoms or amino of from 0 to 4 carbon atoms;

(2)




wherein:

p is 0, 1 or 2; and

R_5 is a group having from 1 to 3 atoms other than hydrogen and is oxy, thio, amino, nitro, cyano, or alkyl;

(3)



wherein:

Y is O, $S(O)_m$, wherein m is 0, 1 or 2, amino or CH_2 ;

R_6 is H or alkyl of from 1 – 3 carbon atoms;


R₇ is hydrogen, or a group of from 0 to 3 atoms other than hydrogen, and is oxy, thio amino, nitro, cyano, or alkyl;

V is an aryl group having 6 annular members comprising 0 to 2 nitrogen atoms and the remainder carbon atoms;

U is a substituent group of from 0 to 5 atoms other than hydrogen, and is oxy, thio amino, nitro, cyano, halo, or alkyl; and

u is 0 to 3; and

(4) diazohexahydroquinoline



wherein:

Z is oxygen, sulfur, NH, alkyl of from 1 to 3 carbon atoms, H or H₂;

R₇ is hydrogen or an organic group of from 1 to 12 carbon atoms and 0 to 4 heteroatoms;

R₈ is hydrogen, an aliphatic group of from 1 to 6 carbon atoms or a heterocycle of from 5 to 6 annular members and from 1 to 2 heteroannular members that are oxygen, nitrogen or sulfur; and

R₉, R₁₀, R₁₃, R₁₄, R₁₅ and R₁₆ are the same or different and are hydrogen or an organic radical of from 1 to 12 carbon atoms or a heterosubstituent of from 1 to 3 heteroatoms;

R_{11} and R_{12} are the same or different and are hydrogen or an organic group of from 1 to 12 carbon atoms.

46. (New): A method according to claim 45, wherein said non-peptide organic molecule is a compound of formula (1).

47. (New): A method according to claim 45, wherein said non-peptide organic molecule is a compound of formula (2).

48. (New): A method according to claim 45, wherein said non-peptide organic molecule is a compound of formula (3).

TRANSMISSION REPORT

:PVJB:650.324.1678 (JUL 27 '05 01:40PM)

```
*****
*
*
* DATE      START    REMOTE TERMINAL      MODE      TIME      RESULTS  TOTAL  DEPT. FILE
*   TIME    IDENTIFICATION                                PAGES  CODE  NO.
*
*
* JUL 27    01:31PM                USPTO G3EST    08'24"    OK        24
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*****
```


PETERS VERNY JONES SCHMITT & ASTON, L.L.P.

Attorneys at Law

425 Sherman Avenue, Suite 230
Palo Alto CA 94306
Telephone: (650) 324-1677
Facsimile: (650) 324-1678

FAX TRANSMISSION COVER SHEET

Date: July 27, 2005

To: Examiner ANDREW K. KOSAR, Ph.D.

Company: United States Patent and Trademark Office

Fax: 1-571-273-0913

Re: USSN: 10/613,754
FILED: 07/02/2003
PVJSA Docket No.: 5008.08-1 (DJA)

Sender: Peters, Verny, Jones, Schmitt & Aston, LLP

YOU SHOULD RECEIVE [25] PAGE(S), INCLUDING THIS COVER SHEET. IF YOU DO
NOT RECEIVE ALL THE PAGES, PLEASE CALL (650) 324-1677.

CONFIDENTIALITY NOTE:

The documents accompanying this facsimile transmission contain information from the law firm of PETERS, VERNY, JONES & SCHMITT, L.L.P., which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named in this transmission sheet above. If you are not the intended recipient, you are hereby notified that any disclosures, copying, and distribution or the taking of any action in reliance on the contents of this facsimile information is strictly prohibited, and that the documents should be returned to this firm immediately. In this regard, if you have received this facsimile transmission in error, please notify us by telephone immediately so that we can arrange for the return of the documents to us at no cost to you.

Original will follow by mail
will not follow by mail ✓

Second Try